![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW BONE METASTASES IN THE ERA OF TARGETED TREATMENTS
The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):129-35
DOI: 10.23736/S1824-4785.19.03204-7
Copyright © 2019 EDIZIONI MINERVA MEDICA
language: English
Quantitative radionuclide imaging of bone metastases
Stijn DE SCHEPPER 1, Philipp RITT 2, Tim Van den WYNGAERT 1, 3, Torsten KUWERT 2 ✉
1 Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium; 2 Clinic of Nuclear Medicine, University-Hospital Erlangen-Nürnberg, Erlangen, Germany; 3 Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
By improving the localization of foci of pathological tracer uptake and offering information on their computed tomography (CT) morphology, single photon emission computed tomography (SPECT)/CT hybrid imaging has considerably improved the diagnostic accuracy of skeletal scintigraphy. SPECT/CT also has the potential to measure tracer uptake in vivo in absolute units. The present article reviews the methodology for and the potential clinical impact of quantitative skeletal scintigraphy.
KEY WORDS: Tomography, emission-computed, single-photon; Tomography, X-ray Computed; Physics; Radionuclide imaging